ReviewHuman vaccines & immunotherapeutics2026
Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus is a highly contagious pathogen and a leading cause of severe diarrhea cases in children under 5 y of age worldwide. Although effective oral rotavirus vaccines have been developed and implemented globally, their performance varies substantially by setting. In high-income countries (HICs), these oral vaccines exhibit 85-90% efficacy in preventing rotavirus-associated hospitalizations, with protection lasting until at least 2 y of age. In contrast, vaccine efficacy in low- and middle-income countries (LMICs) is considerably lower, ranging from approximately 45% to 65%. To address this disparity, efforts are underway to develop next-generation rotavirus vaccines. In this review, we critically examine the immune responses elicited by natural rotavirus infection and by oral vaccination in both HICs and LMICs. The goal is to identify immunological factors associated with durable protection and to define key characteristics that an improved rotavirus vaccine should possess to achieve sustained high efficacy in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.